IPO Plus - IPO

Name▼ / Code▼	Industry	Offer Price	Lot Size	Entry Fee	Closing Date	Grey Market Date▼	Listing Date▲
Minieye Tec 02431.HK	Application Software	17-20.2	200	4,081	2024/12/20	2024/12/24	2024/12/27
Xunfei Healthcare 02506.HK	Application Software	82.8	50	N/A	2024/12/23	2024/12/27	2024/12/30
InnoScience 02577.HK	Semiconductors & Semiconductor Equipment	30.86-33.66	100	3,400	2024/12/23	2024/12/27	2024/12/30
HealthyWay 02587.HK	Health Care Services	7.8-8.8	500	4,444	2024/12/23	2024/12/27	2024/12/30

Name▼

Code▼

Industry

Offer Price

Lot Size

Entry Fee

Closing Date

Grey Market Date▼

Listing Date▲

Minieye Tec
02431.HK

Application Software

17-20.2

200

4,081

2024/12/20

2024/12/24

2024/12/27

Xunfei Healthcare
02506.HK

Application Software

82.8

N/A

2024/12/23

2024/12/27

2024/12/30

InnoScience
02577.HK

Semiconductors & Semiconductor Equipment

30.86-33.66

100

3,400

2024/12/23

2024/12/27

2024/12/30

HealthyWay
02587.HK

Health Care Services

7.8-8.8

500

4,444

2024/12/23

2024/12/27

2024/12/30

Summary

We are a special purpose acquisition company, newly incorporated for the purpose of effecting a De-SPAC Transaction. Although we are not limited to, and may pursue targets in any industry or geographic regions, we intend to focus our efforts on identifying high-growth De-SPAC Targets in the “new economy” sector in China, including but not limited to innovative technology, advanced manufacturing, healthcare, life sciences, culture and entertainment, consumer and e-commerce, green energy and climate actions industries that align with the national economic trends and industrial policies. See “Business — Market Opportunities.” Leveraging the collective network, knowledge and experience of our Promoters and Directors, we plan to effect a De-SPAC Transaction with a high-quality company with competitive edges in the industry and favorable long-term growth prospects. As of the date of this listing document, we have not selected any potential De-SPAC Target and we have not, nor has anyone on our behalf, engaged in any substantive discussions, directly or indirectly, with any potential De-SPAC Target with respect to a De-SPAC Transaction. De-SPAC Transaction opportunities will be sourced from our Promoters’ and Directors’ proprietary network of executives, investors and advisors. Our Promoters and Directors will employ a disciplined and highly selective identification process and expect to add value to a target business by leveraging our Promoters’ and Directors’ networks, relationships and experience, and executing capital structure optimization, operational improvements and add-on acquisitions when opportunities arise. OUR PROMOTERS Our Promoters are CNCB Capital, Zero2IPO Group, Zero2IPO Capital, Mr. NI Zhengdong, Mr. LI Zhu and Mr. LAU Wai Kit. Zero2IPO Group and Zero2IPO Capital are ultimately controlled by Mr. Ni. Mr. Ni and Mr. Li are executive Directors and senior management of our Company. Mr. Lau is a non-executive Director of our Company. As of the date of this listing document, CNCB Capital, Zero2IPO Group, Zero2IPO Capital, Mr. Ni, Mr. Li and Mr. Lau indirectly hold 35%, 15%, 15%, 10%, 20% and 5% of our issued Class B Shares, respectively. See “Corporate Structure.” CNCB Capital CNCB Capital is a wholly-owned subsidiary of CNCB Investment, which is a subsidiary of CITIC Bank. CNCB Capital is licensed by the SFC to engage in a suite of regulated activities under the SFO, including Type 1 (dealing in securities), Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities. CNCB Capital principally engages in financial and investment banking services, including private equity financing, fund investment and asset management in Hong Kong. With Hong Kong market as its investment platform, and supported by CITIC Bank’s extensive investment network and resources, CNCB Capital serves a broad spectrum of clients, including private enterprises, local and national financial institutions and state-owned enterprises, and is an overseas extension of the comprehensive financial services provided by CITIC Bank. CNCB Capital invests in companies in the Greater China regions to generate capital appreciation. CNCB Capital managed assets with an average collective value of at least HK$8.0 billion for 2019, 2020 and 2021, respectively. As of December 31, 2019, 2020 and 2021, the total capital commitments of the funds managed by CNCB Capital were US$1.1 billion, US$1.1 billion and US$1.6 billion, respectively, and CNCB Capital had assets under management of US$1.1 billion, US$1.1 billion and US$1.5 billion, respectively. As of September 30, 2022, CNCB Capital had assets under management of US$2.1 billion and managed and advised more than 10 private equity funds and fixed-income funds with the total capital commitments of US$2.2 billion, covering industries such as internet, healthcare, logistics and biotech. Through a variety of investment methods, including equity investment in primary and secondary markets, structured financing, bond investments, M&A financing and equity pledge financing, CNCB Capital provides enterprises with funding opportunities. CNCB Capital was recognized as an “Outstanding Underwriter for Standby Letter of Credit” in 2021 by Duration Financial. Source: TechStar Acq-Z (07855) Prospectus (IPO Date : 19/12/2022)
Listing Market	MAIN
Industry	Special Purpose Acquisition Company
Background	Others
Major Business Area	N/A

Corporate Information

Substantial Shareholders	Kung Hung Ka (Total share: 24.71%); (Class A share: 30.88%) [01288] Agricultural Bank of China Limited (Total share: 12.40%); (Class A share: 15.49%) NI Zhengdong & Associates (Total share: 7.99%) Fountainhead Partners Fund VCC sub fund CAPS Fund (Total share: 7.47%); (Class A share: 9.34%) CNCB (Hong Kong) Investment Limited (Total share: 6.99%) Century Private Wealth Management PTE. Ltd. (Total share: 6.16%); (Class A share: 7.69%) Cinda Sinorock Global Portfolio Limited Partnership I (Total share: 6.16%); (Class A share: 7.69%) Goldstream Capital Management Limited (Total share: 4.04%); (Class A share: 5.05%)
Directors	NI Zhengdong (Chairman and Co-Chief Executive Officer and Executive Director) LUO Xuan (Co-Chief Executive Officer and Executive Director) CHEN Yaochao (Co-Chief Operation Officer and Executive Director) LI Zhu (Co-Chief Operation Officer and Executive Director) JIANG Jun (Executive Director) LAU Wai Kit (Non-Executive Director) LI Weifeng (Independent Non-Executive Director) XUE Linnan (Independent Non-Executive Director) ZHANG Min (Independent Non-Executive Director)
Company Secretary	IP Tak Wai
Principal Bankers	Bank of China (Hong Kong) Limited
Solicitors	Wilson Sonsini Goodrich & Rosati, Professional Corporation
Auditors	BDO Limited
Registered Office	Unit No. 1506B, Level 15 International Commerce Centre, 1 Austin Road West Kowloon, Hong Kong
Share Registrars	Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No	(852) 2980-1333
Internet Address	https://www.techstaracq.com/#/
Email Address
Tel No	(852) 2187-8118
Fax No

Real-time Futures	IPO Plus	Company Announcement
Top 20	Highs/ Lows	Company Dividend
Local Indices	DTDC RMB Traded Stocks	Result Announ. Schedule
World Indices	BioTech Stocks	Research Report
China Indices	Second Listing Stocks	Result Announ. News
Index Constituents	Short Selling	Corp. Event Search
H Shares (All)	ADR	Economic Calendar
Red Chips (All)	A+H+ADR	Economic Database
GEM (All)	A+H	Economic Data Chart
Industries	Shareholding Disclosures	World Interest Rates